Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Hack Attack: Biopharma Cyber Chiefs Fight Back

Executive Summary

News that Merck & Co was affected by the recent global ransomware attack hits home the increasing importance of cybersecurity. In Vivo recently hosted a roundtable of information security officers on how to prepare for the growing threat of cyber attack.

You may also be interested in...



Former FBI Cyber Chief Urges More Proactive Approach to Cybersecurity

Medtech companies need to up its game in fighting cybersecurity threats, says former chief of FBI’s cyber operations section. If not dealt with effectively, these threats can affect the function of pacemakers or compromise the intellectual property of manufacturers developing new drugs. While the risks of cyberattacks are growing, industry response has been lackadaisical at best, according to Jerry Bessette.

Expert: New Ransomware Has Potential To Shut Down Medical Devices

A Symantec cybersecurity expert says that while there have been no reports so far of medical devices being affected by the new Petya ransomware worm, device companies should not underestimate its threat and need to work with partners, including hospitals, to prevent potential harm to patients.

WannaCry Cybersecurity Alert Shows Medtech Software Must Look Beyond Quick Fixes

Preventing cyberattacks on medical technology occupies the waking thoughts of device software manufacturers, but the global ransomware episode in mid-May shows that companies must also be alive to threat posed to their provider customers.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

SC099054

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel